Forty-two percent of patients had a PPI on their medication list without indication 8 weeks after discharge, and more than half of these patients still were using PPIs 1 year later.

Compared with propensity-score matched patients without PPI use after discharge, patients with continued PPI use were 27% more likely to develop pneumonia, 17% more likely to develop experience cardiac events, 34% more likely to be .readmitted to the hospital in the subsequent year and 17% greater risk of in increased mortality at two years.

https://journals.lww.com/ccmjournal/fulltext/2024/02000/timely_cessation_of_proton_pump_inhibitors_in.4.aspx

These results are reassuring for management of both underweight and overweight patients with AF.

That said, I would still have reservations about prescribing DOACs in the small minority of patients with BMI >45 kg/m2 or body weight >330lbs due to their underrepresentation in the pivotal trials and when you look at the supplementary data you will see a weight of 262 was 95% tile so >330 would be around the 99th %tile of weight.


https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066279

Nurse Practitioners prescribe medications off the beers list at the same rate at primary care physicians, hard to tell what this means for patient care and patient outcomes. 


https://www.acpjournals.org/doi/10.7326/M23-0827?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Using the Brain Care Score seem to be effective in predicting the risk of dementia

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10725202/#:~:text=A%20five%2Dpoint%20higher%20BCS,%25)%20among%20those%20aged%20%3E59.

Even when starting DAPT within 72hours of symptom onset for individuals with minor stroke or TIA the benefit of DAPT for the first 21 days was still seen at 90 day follow up in the form of less recurrent stroke

https://www.nejm.org/do/10.1056/NEJMdo007334/full/

In those high risk patients -- usually with lung or GI cancer they did benefit from primary prevention VTE prophalaxis with a NNT of 6-7 for VTE and death at 6 months. 

https://pubmed.ncbi.nlm.nih.gov/37733336/#:~:text=Conclusions%20and%20relevance%3A%20In%20this,safety%20concerns%2C%20and%20with%20reduced

Just get he biopsy at less than 6 weeks after starting therapy as the yield was the same at 2 weeks as it was at 4-6 weeks


https://pubmed.ncbi.nlm.nih.gov/36642440/

Evidence against baby walker is not enough regarding its negative effect on child development. This subject needs to be addressed more, considering a large number of baby walker users worldwide.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703622/


Surveillance System data from 1990 to 2014 

 230 676 children <15 months old were treated for infant walker–related injuries in US emergency departments from 1990 to 2014.

9 out of every 10 injuries were to the head and neck and 74% were injuries secondary to falling down the stairs in an infant walker

https://publications.aap.org/pediatrics/article-abstract/142/4/e20174332/37420/Infant-Walker-Related-Injuries-in-the-United?redirectedFrom=fulltext?autologincheck=redirected

During average follow-up of in this study the incidence of prostate cancer was less than 1% — and not significantly different 
 Remember most of these pts had testosterone levels around 350 ish give or take so the safety of longer-duration treatment — or treatment resulting in higher blood levels of testosterone — remains unclear.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2813293

From a mean score of 45 points at baseline, mood improved by about 5 points in the placebo group and 6 points in the testosterone group — a statistically significant but small difference. I think you will be hard pressed to find anyone that thinks this is clinically significant except for maybe the authors of the paper when they write that it is beneficial in their conclusion

https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/clinem/dgae026/7516050?redirectedFrom=fulltext&login=true